Wechselwirkungen · Isentress
ISENTRESS 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-119141 · Präparat HOS-094905
Agents that increase gastric pH Population pharmacokinetic analysis from ONCEMRK (Protocol 292) showed that co-administration of raltegravir 1,200 mg once daily with PPIs or H2 blockers did not result in statistically significant changes in the pharmacokinetics of raltegravir. Comparable efficacy and safety results were obtained in the absence or presence of these gastric pH-altering agents. Based on these data, proton pump inhibitors and H2 blockers may be co-administered with raltegravir 1,200 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T13:16:00Z · SHA-256 6b95e5ffe7a0fcf11532bc18fa0933606a4dfe39d9d876e4b916acb6d89e55cc · Passage 3886c399ebf572dc1f3f41a0814b7a745ce6a33ea6fc8e5d5f624e0611432a43 · Zeichen 3779–4294 im Abschnitt